Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells.
Sánchez-Duffhues G, Williams E, Benderitter P, Orlova V, van Wijhe M, Garcia de Vinuesa A, Kerr G, Caradec J, Lodder K, de Boer HC, Goumans MJ, Eekhoff EMW, Morales-Piga A, Bachiller-Corral J, Koolwijk P, Bullock AN, Hoflack J, Ten Dijke P. Sánchez-Duffhues G, et al. Among authors: caradec j. JBMR Plus. 2019 Oct 7;3(11):e10230. doi: 10.1002/jbm4.10230. eCollection 2019 Nov. JBMR Plus. 2019. PMID: 31768489 Free PMC article.
Development of small macrocyclic kinase inhibitors.
Ma J, Sanchez-Duffhues G, Caradec J, Benderitter P, Hoflack J, Dijke PT. Ma J, et al. Among authors: caradec j. Future Med Chem. 2022 Mar;14(6):389-391. doi: 10.4155/fmc-2021-0342. Epub 2022 Jan 14. Future Med Chem. 2022. PMID: 35029506 Free article. No abstract available.
Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
Nouri M, Massah S, Caradec J, Lubik AA, Li N, Truong S, Lee AR, Fazli L, Ramnarine VR, Lovnicki JM, Moore J, Wang M, Foo J, Gleave ME, Hollier BG, Nelson C, Collins C, Dong X, Buttyan R. Nouri M, et al. Among authors: caradec j. Clin Cancer Res. 2020 Apr 1;26(7):1678-1689. doi: 10.1158/1078-0432.CCR-19-0098. Epub 2020 Jan 9. Clin Cancer Res. 2020. PMID: 31919137
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R. Nouri M, et al. Among authors: caradec j. Oncotarget. 2017 Mar 21;8(12):18949-18967. doi: 10.18632/oncotarget.14850. Oncotarget. 2017. PMID: 28145883 Free PMC article.
Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.
Tse BWC, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG. Tse BWC, et al. Among authors: caradec j. Oncogene. 2017 Jun 15;36(24):3417-3427. doi: 10.1038/onc.2016.482. Epub 2017 Jan 16. Oncogene. 2017. PMID: 28092670 Free PMC article.
16 results